The protective effect of cilostazol on transverse rectus abdominis myocutaneous flap in rats

Basit Öğe Kaydı
dc.authorscopusid57209119427
dc.authorscopusid16024976400
dc.authorscopusid16416838000
dc.authorscopusid13611402200
dc.contributor.authorÖzdemir, Ayfer
dc.contributor.authorOrhan, Erkan
dc.contributor.authorAltun, Serdar
dc.contributor.authorİnözü, Emre
dc.date.accessioned2022-05-11T14:36:52Z
dc.date.available2022-05-11T14:36:52Z
dc.date.issued2017
dc.departmentFakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Plastik, Rekonstrüktif ve Estetik Cerrahi Ana Bilim Dalı
dc.description.abstractObjective: Transverse Rectus Abdominis Myocutaneous (TRAM) flap is commonly used in breast reconstruction. The aim of this study is to demonstrate the effects of cilostazol on TRAM flap viability in a rat TRAM model. Methods: Twenty-four Wistar rats were used. They were divided into four groups. Rats in Group 1 were applied TRAM flap. In Group 2, cilostazol 30 mg/kg was administered to rats via oral gavage 3 hours before the flap surgery. After the flap surgery, cilostazol 30mg/kg was administered via oral gavage twice a day for 7 days. In Group 3 before the flap surgery, cilostazol 30 mg/kg was administered via oral gavage twice a day for 7 days, and treatment continued for 7 more days after the flap surgery. In Group 4 before the flap surgery, cilostazol 30 mg/kg was administered via oral gavage twice a day for 7 days and treatment was discontinued after the flap surgery. Result: The mean necrosis rate in Group 1 was 41.69%, in Group 2 it was 27.0%, in Group 3 it was 6.66%, and in Group 4 it was 11.2%. The necrosis rate in Group 1 was found to be statistically significantly higher than other groups (p < .01), the necrosis rate in Group 2 was found to be statistically significant higher than Groups 3 and 4 (p < .01), and the necrosis rate in Group 4 was found to be statistically significant higher than Group 3 (p < .01). Conclusion: Cilostazol treatment seemed to increase the viability of TRAM flap, especially when administered as adjuvant therapy.
dc.identifier.doi10.1080/2000656X.2016.1237958
dc.identifier.endpage222
dc.identifier.issn2000-656X
dc.identifier.issn2000-6764
dc.identifier.issue3en_US
dc.identifier.pmid27707079
dc.identifier.scopus2-s2.0-84990174347
dc.identifier.scopusqualityQ2
dc.identifier.startpage217
dc.identifier.urihttps://doi.org/10.1080/2000656X.2016.1237958
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8450
dc.identifier.volume51
dc.identifier.wosWOS:000401517600011
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorOrhan, Erkan
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofJournal of Plastic Surgery and Hand Surgery
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectTRAM flap
dc.subjectcilostazol
dc.subjectflap viability
dc.subjectEndothelial Growth-Factor
dc.subjectTram Flap
dc.subjectMusculocutaneous Flap
dc.subjectIntermittent Claudication
dc.subjectModel
dc.subjectReconstruction
dc.subjectInhibitor
dc.subjectViability
dc.subjectIschemia
dc.subjectFlow
dc.titleThe protective effect of cilostazol on transverse rectus abdominis myocutaneous flap in rats
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
8450.pdf
Boyut:
690.5 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu